
    
      This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy,
      and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a
      functional, well-differentiated NET, with carcinoid symptoms, treated for at least 2 months
      with Sandostatin LAR at doses of 10 mg, 20 mg, or 30 mg before the start of the Sandostatin
      LAR Last Dose Assessment Phase (Day -28).
    
  